{"nctId":"NCT01614574","briefTitle":"Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease","startDateStruct":{"date":"2012-03-02","type":"ACTUAL"},"conditions":["Gaucher Disease"],"count":6,"armGroups":[{"label":"Investigational","type":"EXPERIMENTAL","interventionNames":["Biological: velaglucerase alfa"]}],"interventions":[{"name":"velaglucerase alfa","otherNames":["VPRIV","Gene activated human glucocerebrosidase"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has a documented diagnosis of Gaucher disease\n* The patient is at least 2 years of age\n* Female patients of child bearing potential must agree to use a medically acceptable method of contraception at all times during the study\n* The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC)\n* The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator\n\nPatients who are switched from imiglucerase ERT must meet the following additional criteria:\n\n* Received treatment with imiglucerase for a minimum of 12 consecutive months\n* Meet predefined limits for hemoglobin concentration and platelet counts\n\nPatients na√Øve to treatment for Gaucher disease must meet the following additional criteria:\n\n* Not received treatment for Gaucher disease (investigational or approved products) within 12 months prior to study entry\n* Have Gaucher disease related anemia and at least one of the following: moderate splenomegaly or, Gaucher disease-related thrombocytopenia or Gaucher disease-related enlarged liver\n\nExclusion Criteria:\n\n* Treatment with any investigational drug or device within the 30 days prior to study entry (time of informed consent); such use during the study is not permitted\n* Positive for hepatitis B or hepatitis C.\n* Non-Gaucher disease related anemia\n* The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study\n* Significant comorbidity, as determined by the Investigator that might affect study data or confound the study results\n* The patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator\n* The patient has experienced a severe (grade 3 or higher) infusion-related hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT (approved or investigational)\n* Currently receiving red blood cell growth factor, (eg, erythropoietin) or chronic systemic corticosteroids in the last 6 months\n* Patient has had a splenectomy or the patient has an active, clinically significant spleen infarction within 12 months of screening\n* Patient has worsening bone necrosis within 12 months of screening\n* The patient is pregnant or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Severe Adverse Events (SAE)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Treatment Emergent Adverse Events (TEAE)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"PRIMARY","title":"Development of Anti-velaglucerase Alfa Antibody","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Infusion- Related Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Concomitant Medication","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.729"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Platelet Count","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"35.75"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Liver Volume, Normalized to Body Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.148"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Spleen Volume, Normalized to Body Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.067"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Chitotriosidase Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.3","spread":"64.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CCL18 Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"10.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["NASOPHARYNGITIS","CONTUSION","ARTHRALGIA","RETINOPATHY PROLIFERATIVE","VISUAL ACUITY REDUCED"]}}}